ORCID Profile
0000-0001-5521-9884
Current Organisation
RMIT University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: American Chemical Society (ACS)
Date: 13-04-2017
DOI: 10.1021/ACS.INORGCHEM.7B00410
Abstract: The tin(IV) compounds Me
Publisher: Elsevier BV
Date: 02-2018
DOI: 10.1016/J.EJMECH.2017.12.048
Abstract: Newly synthesised mononuclear gold complexes containing the 2-BrC
Publisher: American Chemical Society (ACS)
Date: 31-05-2023
Publisher: American Chemical Society (ACS)
Date: 15-04-2019
DOI: 10.1021/ACS.INORGCHEM.9B00281
Abstract: A series of alkynylgold(I) phosphine complexes containing methoxy-substituted cinnamide moieties (3a-3c and 4a-4c) have been synthesized and characterized. All of the synthesized complexes were evaluated for their cytotoxicity against three human cancer cell lines A549 (lung), D24 (melanoma), and HT1080 (fibrosarcoma) and the human embryonic kidney 293 cell line (Hek293T) as a proxy model for noncancer cells. Most of the synthesized compounds showed antiproliferative activity against cancer cell lines at low micromolar concentrations. Among these, complex 3c showed a broad spectrum of anticancer activity with IC
Publisher: Wiley
Date: 30-09-2019
Abstract: Four cycloaurated phosphine sulfide complexes, [Au{κ
Publisher: American Chemical Society (ACS)
Date: 14-07-2020
Publisher: Oxford University Press (OUP)
Date: 24-06-2021
Abstract: Increasingly explored over the last decade, gold complexes have shown great promise in the field of cancer therapeutics. A major obstacle to their clinical progression has been their lack of in vivo stability, particularly for gold(III) complexes, which often undergo a facile reduction in the presence of biomolecules such as glutathione. Herein, we report a new class of promising anticancer gold(I)–gold(III) complexes with the general formula [XAuI(μ-2-C6F4PPh2)(κ2-2-C6F4PPh2)AuIIIX] [X = Cl (1), Br (2), NO3 (3)] which feature two gold atoms in different oxidation states (I and III) in a single molecule. Interestingly, gold(I)–gold(III) complexes (1–3) are stable against glutathione reduction under physiological-like conditions. In addition, complexes 1–3 exhibit significant cytotoxicity (276-fold greater than cisplatin) toward the tested cancer cells compared to the noncancerous cells. Moreover, the gold(I)–gold(III) complexes do not interact with DNA-like cisplatin but target cellular thioredoxin reductase, an enzyme linked to the development of cisplatin drug resistance. Complexes 1–3 also showed potential to inhibit cancer and endothelial cell migration, as well as tube formation during angiogenesis. In vivo studies in a murine HeLa xenograft model further showed the gold compounds may inhibit tumor growth on par clinically used cisplatin, supporting the significant potential this new compound class has for further development as cancer therapeutic.
Publisher: Wiley
Date: 02-10-2019
Publisher: Royal Society of Chemistry (RSC)
Date: 2018
DOI: 10.1039/C8DT01724G
Abstract: Herein we report the synthesis of gold( i ) and gold( iii ) complexes of tris(4-methoxyphenyl)phosphine and tris(2,6-dimethoxyphenyl)phosphine and their anticancer activity towards 2D and 3D cancer models.
Publisher: American Chemical Society (ACS)
Date: 28-08-2017
Publisher: Royal Society of Chemistry (RSC)
Date: 2019
DOI: 10.1039/C8DT03875A
Abstract: Rare palladium compounds containing a diphosphine and a Sn,As-based chelate ligand for cancer treatment.
Publisher: American Chemical Society (ACS)
Date: 07-04-2020
No related grants have been discovered for Steven Privér.